DGX vs PFE: fair value comparison
Quest Diagnostics Incorporated and Pfizer Inc. · Updated 2026-10-19
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, DGX currently sits closer to the top of our ranking by discount to fair value. DGX carries the stronger quality grade.
| DGX | PFE | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $230.97 | $28.28 |
| 12-month range | $173.49–$247.45 | $23.67–$29.58 |
| Rank by discount to fair value | #82 of 108 Healthcare | #84 of 108 Healthcare |
| Quality grade | B | C |
| Leverage | Moderate | Moderate |
| Margin trend | Stable | Expanding |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Overbought |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: DGX fair value analysis · PFE fair value analysis